Posts tagged safety profile
Roth starts Global Blood Therapeutics at buy

Roth Capital Partners initiated coverage of Global Blood Therapeutics (NASDAQ:GBT) as a “Focus Pick” with a “buy” rating and price target of $47. The stock closed at $17.45 on Monday

“In our view, Global Blood Therapeutics represents an attractive investment opportunity because its lead product, GBT440, has the potential to improve the standard of care for patients who suffer from sickle cell anemia (SCA),” writes analyst Mark Breidenbach.

Read More
Leerink downgrades Mirna to market perform

Leerink Partners downgraded Mirna Therapeutics (NASDAQ:MIRN) to “market perform” from “outperform” and lowered its price target to $4 from $10, citing added uncertainties around the development path and safety profile of lead product candidate, MRX34. The stock closed at $3.95 on Tuesday.

“While microRNAs represent an intriguing emerging new class of therapeutic targets, recent company updates render us more cautious on the prospects for Mirna shares,” writes analyst Michael Schmidt.

Read More
Mackie starts Profound Medical at speculative buy

Mackie Research Capital initiated coverage of Profound Medical (TSX-V:PRN) with a “speculative buy” rating and 12-month target price of $3.30. The stock was quoted at $1.45 at mid-day on Wednesday.

Read More
Ocular Therapeutix to initiate Phase 3 program with OTX-TP

Ocular Therapeutix (NASDAQ:OCUL) has completed an end-of-Phase 2 review with the FDA for its sustained release travoprost product candidate, OTX-TP, for the treatment of glaucoma and ocular hypertension and intends to initiate the first of two Phase 3 clinical trials during the third quarter of 2016.

The FDA has stated that it agrees with the overall Phase 3 clinical development program proposed by Ocular in its briefing package submitted to the FDA.

Read More
HCW starts Tobira Therapeutics at buy

H.C. Wainwright has initiated coverage of Tobira Therapeutics (NASDAQ:TBRA) with a “buy” rating and $22 price target. The stock closed at $7.30 on Friday.

Tobira is focused on the development of a sole drug candidate, cenicriviroc (CVC), as a treatment for non-alcoholic steatohepatitis (NASH). NASH is a disease of the liver that can lead to fibrosis, cirrhosis, and ultimately, transplant or hepatocellular carcinoma.

Read More